Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist. - 2The Best Web-based Courses for Expertise Improvement
- 3The Best Computer games Ever
- 4Europe pledges over €15bn for clean energy for Africa
- 5Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis
- Exploring the Main Year of Life as a parent: Individual Encounters
- People are getting their news from AI – and it’s altering their views
- First SpaceX booster for upgraded Starship fails during test in Texas
- When fake data is a good thing – how synthetic data trains AI to solve real problems
- Audits of 6 European Busssiness Class Flights
- Accor signs agreement to transform El Gouna resort as Sofitel
- Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
